Genmab CEO: Three products may turn into five this year

Normally, it takes ten months for a marketing authorization to be processed in the US. Genmab hopes for an accelerated process, so the firm can get approval for two new products this year.

Photo: Tuala Hjarnø / Genmab / PR

Genmab's three winning horses may very well turn into five in the course of 2021.

"The most important milestone this year is that we hope to get two new products approved, which are basically created with Genmab techology. One is Johnson & Johnson's Amivantamab, and the other is Tisotumab Vedotin," Genmab CEO Jan van de Winkel tells Ritzau Finans.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs